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1. Introduction 
Large-scale analysis of total genome transcripts (transcriptome) in organisms including 
human and mouse has revealed that many RNAs are transcribed from genomic regions that 
encode no proteins (referred to as ncRNA) (1-5). Among such ncRNAs, microRNAs 
(miRNAs), small molecule RNAs 18-28 bases long, have been extensively studied over the 
past decade, and a gene regulatory system called “RNA silencing” has been revealed. In 
humans, more than 400 miRNAs are known to regulate at least one-third of protein-
encoding genes (6-10). Most miRNAs are generated by processing of long miRNA 
precursors (pri-miRNAs) (6, 9). Pri-miRNAs are transcribed by RNA polymerase II and 5’ 
cap structures and poly A tails are added, similarly to protein-encoding mRNAs. Pri-
miRNAs are further processed in the nucleus into pre-miRNAs with an approximately 70 
base hairpin structure and are then exported to the cytoplasm. pre-miRNAs are finally 
processed into mature miRNAs by the enzyme, Dicer. It is noteworthy that miRNAs are 
sometimes encoded in the introns of other genes. A mature miRNA is incorporated into the 
RNA-induced silencing complex to act on its target mRNA. Broadly speaking, miRNAs can 
act on mRNAs in two ways. If there is limited homology between an miRNA and a target 
mRNA, the miRNA suppresses translation of the mRNA. However, if the miRNA has 
complete or nearly complete homology with a target mRNA, the mRNA is rapidly 
degraded. In animal cells, the former scenario usually occurs (7, 10-12). Many miRNAs have 
been reported to be associated with tumors, including AML and glioma; however, it is still 
unclear how predominant miRNAs are in tumorigenesis.  
Relatively large ncRNAs of over several hundred bases, which are longer than pri-miRNAs 
whose length is usually 200-300 bases, are called long-chain non-coding RNAs (lncRNAs). 
Despite their somewhat unclear definition and their largely undetermined functions (13), 
the public databases for lncRNAs, for example, lncRNAdb (http://www.lncrnadb.org/) (14) 
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or NONCODE (http://www.noncode.org) (15), contain several hundred mammalian 
lncRNAs, including more than 100 from human (16). The RNAs included are heterologous; 
some localize in the nucleus to form certain structures, others interact with chromatin 
modifying enzymes such as p300, while others function in the cytoplasm (Fig. 1). 
Both miRNAs and lncRNAs are physiologically important in many biological processes, 
including development and cell differentiation. Their association with disease, especially 
cancers, is of great interest (5). Association of miRNAs with various tumors, including 
different types of leukemia (Table 1) and glioma (Table 2), has been demonstrated. They 
sometimes act as tumor-promoting factors and sometimes as tumor suppressors. Expression 
of many lncRNAs, including NDM29 (neuroblastoma) (17, 18) and MALAT-1 (lung cancer) 
(19) are correlated with tumor progression, while MEG3 (pituitary tumor) (20, 21), HOTAIR 
(breast carcinoma) (22), H19 (Wilms’ tumor) (23), AK023948 (papillary thyroid tumor) (24) 
and LOC285194 (osteosarcoma) (25) are putative tumor suppressors (Table 3). These 
lncRNAs seem to control cancer cell growth by regulating other genes (NDM29, HOTAIR, 
H19) or by adjusting the mRNA splicing mechanism (MALAT-1) (Fig. 1) (14). 
 
Figure 1. Classification of ncRNAs. (a) Pri-miRNAs are synthesized and processed in the nucleus, then 
exported to the cytoplasm. They are incorporated in the RISC complex to degrade or inhibit 
transcription of target mRNAs. However, some synthesized lncRNAs associate with chromatin (b) to 
silence certain genes. Some lncRNAs are incorporated in intranuclear bodies (c) or make complexes 
with specific proteins (d). Some are exported to the cytoplasm to work in the RNA-protein complex (e). 
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Name Loci Name Loci
Oncogenic or Increased Expression in AML Tumor Suppressive or Decreased Expression in AML 
let-7b 22q13.31 let-7 9q22.32 
let-7e 19q13.41 let-7b 22q13.31 
miR-10a 17q21.32 miR-9* 1q22 
miR-10b 2q31.1 miR-15a 13q14.2 
miR-27a 19p13.13 miR-15b 3q25.33 
miR-30d 8q24.22 miR-16 13q14.2 
miR-126 9q34.3 miR-19a 13q31.3 
miR-129-5p 7q32.1 miR-20a 13q31.3 
miR-130b 22 miR-26a 3p22.2 
miR-142-5p 17q22 miR-29a 7q32.3 
miR-155 21q21.3 miR-29b 7q32.3 
miR-181a 1q31.3/9q33.3 miR-29c 1q32.2 
miR-181b 1q31.3/9q33.3 miR-30a-3p 6q13 
miR-181c 19p13.13 miR-34b 11q23.1 
miR-181d 19p13.13 miR-34c 11q23.1 
miR-195 17p13.1 miR-124 8p23.1 
miR-221 Xp11.3 miR-128-1 2q21.3 
miR-223 Xq12 miR-145 5q32 
miR-221/222 Xp11.3 miR-147 9q33.2 
miR-324-5p 17p13.1 miR-148a 7p15.2 
miR-326 11q13.4 miR-151 8q24.3 
miR-328 16q22.1 miR-181a 1q31.3/9q33.3 
miR-331 12q22 miR-181b 1q31.3/9q33.3 
miR-340 5q35.3 miR-182 7q32.2 
miR-374 Xq13.2 miR-184 15q25.1 
miR-424 Xq26.3 miR-194 1q41 
  miR-196a 17q21.32 
  miR-196a 17q21.32 
  miR-199a 19p13.2 
  miR-204 9q21.12 
  miR-219-5p 6q21.32 
  miR-220a Xq25 
  miR-302b* 4q25 
  miR-302d 4q25 
  miR-320 8q21.3 
  miR-320 8q21.3 
  miR-325 Xq21.1 
    
 
Data are chosen from references 54, 55, 62, 63, 65, 66. Data confined to cytogenetically normal AML where possible. 
Note some miRNA appeared both oncogenic and tumor-suppressive. 
Table 1. Examples of miRNAs associated with AML that change expression level 
 Oncogene and Cancer – From Bench to Clinic 418 
 
 
 
 
 
Name Genetic Locus Name Genetic Locus 
Oncogenic or Increased Expression in Glioma Tumor Suppressive or Decreased Expression in Glioma 
miR-9* 1q22 let-7 family 9q22.32 
miR-10a* 17q21.32 miR-7 9q21.32 
miR-10b 2q31.1 miR-15b 3q25.33 
miR-17/92 cluster 13q31.3 miR-17 13q31.3 
miR-21 17q23.1 miR-26b 2q35 
miR-25 7q22.1 miR-29b 7q32.3 
miR-26a 3p22.2 miR-34a 1p36.22 
miR-93 7q22.1 miR-101 1p31.3 
miR-125b 11q24.1 miR-106a Xq26.2 
miR-182 7q32.2 miR-124 8p23.1 
miR-195 17p13.1 miR-125a 19q13.41 
miR-196a 17q21.32 miR-128 2q21.3 
miR-196b 7p15.2 miR-137 1p21.3 
miR-221/222 Xp11.3 miR-146b/146b-5p 10q24.32 
miR-296 20q13.32 miR-153 2q35 
miR-381 14q32.31 miR-181 1q31.3/9q33.3 
miR-455-3p 9q32 miR-184 15q25.1 
miR-486 8p11.21 miR-195 17p13.1 
  miR-199b-5p 9q34.11 
  miR-218 4p15.31 
  miR-326 11q13.4 
  miR-451 17q11.2 
    
 
Data are chosen from references 67 and 68. Data confined to cases of low grade gliomas but exclusion of data from 
high grade glioblastoma is not necessarily complete. Note some miRNAs appeared both oncogenic and tumor-
suppressive. 
 
 
 
Table 2. miRNAs that show altered expression levels in glioma cells 
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Name Alias Mouse 
Homolog 
Genetic 
Locus 
Product 
Length 
(bp) 
Tumor Function Refs 
Tumor promoting or Increased Expression 
AIRN  Airn 6q26 NA Wilms’ tumor NA (59) 
BC200 BCYRN1  Bc1 2p21 200 Breast cancer Regulation of protein 
biosynthesis 
(70) 
HIF1A-AS2 aHIF NA 14q23.2 2051 Multiple 
cancers 
Decoy of mRNA (71) 
HOTAIR Gm16258 Hotair 12q13.3 2364 Multiple  
cancers 
Epigenetic silencing of 
HOXD gene through 
histoneH3K27 methylation 
(72) 
HULC  NA 6p24.3 500 Hepatocellular 
carcinoma 
Post-transcriptional 
regulation 
(73) 
IGF2AS PEG8 Igh2as 11p15.5 2091 Wilms' tumor NA (74) 
KRASP1  NA 6p12-p11 5178 Prostate cancer Decoy of miRNA (75) 
L1PA16  VL30-1a) 3q26.3 833 Many tumor cell 
lines 
Activation of proto-
oncogene 
(76) 
MALAT1 Neat2 Malat1 11q13.1 8708 Multiple cancer Control of RNA procession (19, 77) 
MER11C HERVK11 VL30-1a) 11p11.1 1060 Many tumor cell 
lines 
Activation of proto-
oncogene 
(76) 
PCA3 DD3 NA 9q21-q22 3735 Prostate cancer NA (78) 
PCGEM1  NA 2q32 1603 Prostate cancer NA (79) 
PRNCR1  NA 8q24 >12756 Prostate cancer NA (80) 
SRA1  Sra1 5q31.3 1955 Breast cancer Activation of nuclear 
receptors 
(81) 
TERC  Terc 3q26 451 Multiple cancer Telomere template (82) 
UCA1 CUDR NA 19p13.12 1591 Bladder cancer Regulation of cell cycle (83) 
WT1-AS WIT1 NA 11p13 1333 Wilms' tumor 
AML 
Downregulation of WT1, 
tumor suppressor 
(84) 
XIST  Xist Xq13.2 19271 Multiple cancers Xinactivation (56, 85) 
Tumor Suppressing or Decreased Expression in Tumor 
AK023948  NA 8q24 2807 Papillary thyroid 
carcinoma 
NA (24) 
ANRIL CDK2BAS, 
p15AS 
NA 9q21 944 Prostate cancer, 
breast cancer, 
melanoma, and 
other tumors 
Regulation of epigenetic 
transcriptional repression 
(58) 
BC040587  NA 3q13.31 NA Osteosarcoma NA (25) 
DLEU2  Dleu2 13q14.3 2768 Chronic 
lymphocytic 
leukemia 
pri-miRNA for miR15a and 
miR16 
(86) 
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Name Alias Mouse 
Homolog 
Genetic 
Locus 
Product 
Length 
(bp) 
Tumor Function Refs 
GAS5  Gas5 1q25.1 651 Breast cancer Decoy of glucocorticoid 
receptor 
(87) 
H19  H19 11p15.5 2322 Wilms' tumor Epigenetic regulation 
through DNA methylation 
(88) 
KCNQ1OT1   LIT1, 
KvLQT1-AS, 
KvLQT1OT1 
Kcnq1ot1 11p15 91671 Embryonal cancer 
associated with 
Beckwith-
Wiedemann 
syndrome  
Epigenetic imprinting 
through H3K27 methylation 
(57) 
LOC285194  NA 3q13.31 NA Osteosarcoma NA (25) 
MEG3 Gtl2 Meg3 14q32 1595 Glioma, pituitary 
adenoma and 
other tumor 
Regulation of p53 target 
proteins 
(89) 
NDM29 29A NA 11p15.3 131 Neuroblastoma Induction the appearance of 
neuronal-like properties 
(18) 
p53 mRNA   Tp53 17p13.1 19144 Multiple cancer RNA protein binding, MDM3 (90) 
PTENP1  NA 9p21 3932 Prostate cancer Decoy for PTEN-targeting 
miRNAs 
(75) 
RMRP  Rmrp 9p21-p12 267 Leukemia and 
lymphoma 
Mitochondrial RNA 
processing endoribonuclease, 
hTERT-dependent 
(91) 
TERRA  TelRNAs telomere 
repeats 
NA Many cancer cell 
lines 
Interaction with the TRF1 (92) 
vtRNA2-1  NA 5q31.1 100 AML, papillary 
thyroid cancer 
Regulation of RNA 
dependent protein kinase 
(pPKR) 
(93) 
ZNFX1-AS1 Zfas1 1500012 
F01Rik 
20q13.13 1020 Breast cancer NA (94) 
(a) no homologous RNA but binds to PSF, a transcriptional repressor. NA, not available. 
Table 3. Human lncRNAs associated with tumors described in public data bases. 
2. Genetic abnormality observed in acute myeloid leukemia (AML) 
AML, which comprises approximately 25% of hematopoietic malignancies, has 
heterogeneous clinical features and variable responses to contemporary therapy (26). 
Genetic alterations are often observed in AML cells and the clinical heterogeneity of the 
disease is considered to reflect the genetic diversity of these cells (27, 28). It is very 
important to study the genetic mutations in AML cells to fully understand the cause of the 
disease. However, genetic lesion(s) responsible for AML, such as the loss or gain of a certain 
gene, have not yet been fully elucidated. Indeed, the complex features of AML suggest that 
the genetic cause of this disease is multifactorial (29). Several protein-encoding genes have 
been identified that are useful for indicating the prognosis of the disease (30-32). These 
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include RUNX1 (AML1)-RUNX1T1 (ETO) and CBFB-MYH11, which are associated with 
specific chromosomal mutations, t(8;21)(q22;q22) and inv(16)(p13;q12)/t(16;16)(p13;q22), 
respectively. AML with these cytogenetic features (singly or together) represents about 15% 
of de novo AML. The patients with these diagnostic criteria are classified in the favorable 
clinical outcome group (standard-risk group). Several other chromosomal abnormalities 
have been recurrently observed, as described in the WHO classification. AML with balanced 
or unbalanced translocations involving the MLL gene located on chromosome 11 are also 
well documented and are mostly classified in the intermediate-risk group. Meanwhile, AML 
patients with a normal karyotype and no cytological abnormality include cases classified in 
the unfavorable (adverse-risk) or intermediate-risk group. Moreover, a genetic abnormality 
of the FL3 gene (internal tandem repeat) is found in many AML subtypes and, in 
combination with a wild-type NPM gene, contributes to poor prognosis (31). Recently, 
Paschka and colleagues have revealed that the genes encoding the metabolic enzymes, 
isocitrate dehydrogenase 1 and 2 (IDH1/2) are important for diagnosis and prognosis 
prediction of AML patients (33). These mutations of IDH1/2 change the activity of the 
enzymes to reduce α-ketoglutarate levels and to elevate 2-hydroxyglutarate levels. This 
results in changes to chromatin structure and destabilization of certain gene-regulatory 
proteins, including HIF-1 (34). While cytogenetically normal AML patients with an NPM 
mutation and a normal FL3 gene tend to show favorable outcomes, AML patients with the 
same genetic profile but also with IDH1/2 mutation showed adverse prognosis with poorer 
remission. IDH1/2 mutation was also found in several other tumors, including glioma (35). 
Therefore, a combination of genetic alterations resulting in mutation of specific genes as well 
as cytogenetically apparent chromosomal changes are important for AML malignancy. 
3. AML and CCDC26 
In HL-60 cells derived from AML, a small part of chromosome 8 is excised and amplified as 
an extrachromosomal element, or double minute chromosome (dmin). Dmin is a cytogenetic 
abnormality infrequently observed in AML. The dmin of HL-60 cells consists of several 
repeats of an amplification unit (referred as amplicon) of about 2 million base pairs. The 
amplicon, which is derived from several areas of an approximately 4.6 million base pair 
region of chromosome 8q24, contains an intact MYC oncogene. Besides MYC, several other 
genes, including CCDC26 and tribbles homolog 1 (TRIB1), are also encoded on the amplicon 
(Fig. 2). All are actively transcribed in HL-60 cells. The drug-induced differentiation of HL-
60 cells suppressed the expression of all these genes, indicating that they might be related to 
the cancerous nature of the cells. Some types of cancer cell respond to the anticancer drug 
hydroxyurea by excluding unstable extrachromosomal elements, which then lose their 
proliferative nature. In HL-60 cells, the original MYC genetic locus remained intact after 
dmin was excluded, but was no longer transcribed (36). These observations suggest that the 
expression of genes from dmin, with its altered DNA structure, and from the intact 
chromosome are different, and can be interpreted as being due to aberrant gene expression 
from dmin (including the MYC oncogene). Interestingly, in HL-60 cells, the CCDC26 gene on 
dmin is rearranged as a result of chromosomal rejoining and is amplified in an incomplete 
form to produce abnormal transcripts (37). 
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Figure 2. Depiction of the generation of the discontinuous amplicon unit of dmin in HL-60 cells. Several 
replication initiation bubbles collapse and “corrupted” bubbles reunite to form an amplicon unit. 
Excision of an initial large amplicon (possibly as an episome) might precede replication. The arrows 
numbered 1 through 6 indicate regions reunited in the amplicon. Note that the lengths of the various 
regions are not to scale. Once the amplicon unit has formed, its multimerization results in a dmin. 
A common change occurs at the CCDC26 locus in cytologically dmin-positive AML patients. 
This chromosomal change occurs at a position consistent with the amplified region observed 
in HL-60 cells (38, 39). Furthermore, destruction of the internal structure of the CCDC26 
gene seems to underlie the common mechanism behind the generation of dmin-positive 
AML cells. 
A comprehensive genome-wide study of a group of childhood AML patients revealed that 
CCDC26 was one of the genes with the highest increase in copy number in AML cells. 
Radtke and colleagues investigated chromosome number alteration (CNA) in pediatric 
AML using a comprehensive single nucleotide polymorphism (SNP) array analysis. They 
found the most common CNA, in 14% (15 in 111) of pediatric AML patients, to be in 
 
Is CCDC26 a Novel Cancer-Associated Long-Chain Non-Coding RNA? 423 
chromosome band 8q24 with a low-burden copy number increase (2.83-3.77 copies) (40). 
These included cases of trisomy 8, which frequently occurs in AML (41). The minimum 
altered region common in all 15 of these patients was located in a 20-megabase region of 
8q24, which contains CCDC26. 
Originally, CCDC26 was reported as a gene associated with differentiation and apoptosis of 
PLB985 cells (an HL-60 subclone) following induction by treatment with retinoic acid 
(CCDC26 is also known as RAM, retinoic acid modifying). In cells that have become 
resistant to differentiation and apoptosis after infection of retrovirus, the viral genome was 
seen to be inserted in the intron of CCDC26. Retinoic acid promotes differentiation and 
apoptosis of not only many leukemia cells but also of neuroblastoma and glioblastoma cells 
through transcriptional regulation of many other genes. CCDC26 may have a role with 
retinoic acid in differentiation and growth arrest of these cells (42). 
4. Glioma and CCDC26 
Primary brain tumor (PBT) is a disease with an incidence of 12 in 100,000 per year. Glioma 
accounts for a major part of PBT, and contains cases with different grades of malignancy, 
namely (I) benign glioma, (II) diffuse astrocytoma, (III) anaplastic astrocytoma and (IV) 
glioblastoma (43). Although many genetic abnormalities have been reported in gliomas, a 
single critical lesion responsible for tumorigenesis has not been found. Among these 
abnormalities, mutations occur in genes for DNA repair enzymes, including PRKDC, XRCC, 
PARP1, MGMT, ERCC1, ERCC2, epidermal growth factor and the inflammatory cytokine, 
IL-13. Furthermore, over-expression or amplification of the epidermal growth factor 
receptor gene and deletion of p16INK are correlated with poor survival (43). A genome wide 
association study using SNPs revealed the association of several genes with glioma, 
including telomerase regulating gene TERT, RTEL1, tumor suppressor gene CDKN2A/2B, 
pleckstrin homology-like domain family B member 1 (a protein with unknown function) 
and CCDC26 (44). The CCDC26 gene locus was strongly linked with this glioma by several 
SNPs, including rs4295627, rs16904140, rs6470745, rs891835, and rs10464870 (see Fig. 3a). A 
different SNP in the intergenic region bordering CCDC26, rs987525, was linked to cleft 
palate (45). Notably, cleft palate is also a risk factor of PBT. CCDC26 is, therefore, a potential 
common factor of both conditions. CCDC26 is just one of the risk factors for glioma and 
other genetic risk factors increase glioma incidence cumulatively. Therefore, there might be 
a synergistic effect with other genetic risk factors (46). CCDC26 is not necessarily a risk 
factor of high grade (III-IV) glioma (47). Interestingly, in concordance with the situation for 
AML, the CCDC26 genotype is associated with IDH1/2 mutation in low grade glioma. 
Considering the synergy of CCDC26 with IDH1/2, CCDC26 may have linkage to a 
subpopulation of gliomas with relatively lower grade (46, 48). 
The Gene Expression Omnibus database (GEO; http://www.ncbi.nlm.nih.gov/geo/) (49) 
contains data showing altered CCDC26 expression between normal and tumorigenic cells. 
Expression of CCDC26 is higher in myeloid leukemia cell lines, namely KG-1, THP-1 and 
U937, compared with normal monocytes (GEO dataset accession ID; GDS2251), and is 
higher in sporadic basal-like cancer compared with normal cells (GD2250). On the other 
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Figure 3. (A) Summary of genetic locus 8q24.31. The scale indicates the region 8q24.31 (130.35 Mb to 
130.71 Mb; numbering is based on human genome assembly 37.1). Marks on the scale indicate the 
locations of five SNPs that are linked to glioma (open circles; rs4295627, rs16904140, rs6470745, rs891835 
and rs10464870, left to right), three miRNAs registered in the public database (filled circles; mir-3669, 
mir-3673 and mir-3686, left to right) and a retrovirus insertion site (filled square) within the introns of 
CCDC26. Below the scale, which covers a 350-kb region, major variants of CCDC26 mRNA (long and 
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short) are shown. The long transcript consists of four (1-2-3-4) exons, and the short transcripts consist of 
three (1a-3-4) or four (1a-2a-3-4) exons. All variants share exon 3 and 4, in which the hypothetical open 
reading frame is encoded. Locations of the amplified region in HL-60 cells and the commonly amplified 
region (MAR) in childhood AML are shown with filled rectangles. The hypothetical open reading frame 
encoded in exons 3 and 4 is not included in the region amplified in HL-60 cells. The pattern of histone 
H3K27 acetylation, activity of transcription in leukemia cell lines, and bar plots for conserved synteny 
between human and each organism (m: mouse, d: dog, e: elephant and o: opossum) obtained from the 
UCSC Genome Browser (95) are shown. Actively transcribed regions that are not the major exons of 
CCDC26 mRNA are indicated by grey rectangles. (B) Optimal alignment of the CCDC26 exon 3-4 
encoded ORF and the region of conserved synteny on mouse chromosome 15. A possible ORF (94 
amino acids) in the mouse sequence is totally mismatched with that of human by frameshift changes. 
hand, CCDC26 expression is decreased in hyperplastic enlarged lobular units considered as 
the earliest precursors of breast cancer compared with normal units (GDS2739). Increased 
CCDC26 expression is associated with malignancy progression in some cancerous cells. 
CCDC26 expression was increased in CD133 positive neurosphere-like glioma cell lines 
compared with CD133 negative adherent glioma cell lines (GDS2728), and was increased in 
alveolar macrophages of cigarette smokers comparison with macrophages of non-smokers 
(GDS3496). Increased expression of CCDC26 might mean this gene is tumorigenic or 
oncogenic. However, the relationship of altered CCDC26 expression to malignancy is still 
ambiguous. 
5. Overview of the CCDC26 genetic locus 
As described in the previous section, all SNPs associated with glioma, and a retrovirus 
insertion site where virus insertion makes AML cells resistant to retinoic acid (42) are 
located in the intron of CCDC26 (Fig. 3a). Exon 4, which encodes the majority of a 
hypothetical open reading frame (ORF), is not amplified in pediatric AML or in AML-
derived HL-60 cells. The exonic sequence of CCDC26 is not well conserved in other species, 
including mouse, and an ORF has no homology with known proteins. These data strongly 
suggest that CCDC26 does not function as a protein-encoding RNA; rather it functions as a 
ncRNA. Highly conserved regions in the intron sequence of CCDC26 suggest the existence 
of another intronic ncRNA. As mentioned above, the CCDC26 locus is rearranged in the 
genome of HL-60 cells. It is plausible that the ncRNA encoded by this locus is important for 
the growth of these cells. 
A short putative ORF encoding a protein or with a length of 109 amino acids is present in 
the CCDC26 exons; there is no other ORF of more than 50 amino acids. This actual protein, 
however, has not been observed. Moreover, orthologous proteins are not found in any other 
organism. For example, a loosely homologous sequence of human exon 4, found in the 
mouse chromosome 15 region of conserved synteny, with an ORF of 94 amino acids is 
actively transcribed in mouse leukemia cells (T. Hirano unpublished observation). However, 
this ORF is completely different from the human sequence and even contains frame shift 
alterations (Fig. 3b). This indicates that the putative protein encoded by CCDC26 has no 
conserved function among species. Although this ORF may be coincidental due to the 
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absence of stop codons, an interesting possibility is that this unique protein has newly 
emerged during human evolution. mRNA stability is influenced by whether an ORF is 
encoded because nonsense mediated RNA decay, a mechanism associated with quality 
control of mRNA, rapidly degrades mRNAs that are not useful as templates for protein 
synthesis. Absence of an ORF in an mRNA promotes degradation by this mechanism, 
however, the existence of a CCDC26 protein will prolong the lifetime of CCDC26 mRNA and 
may maintain the function (if any) of the RNA itself. 
Because of the considerable length of the CCDC26 intron (330 kbp versus 1200 bp exons), it 
is very difficult to ignore the possibility that there is another transcript(s) within this intron 
with important function. Possible encoded ncRNAs within the CCDC26 exon-intron region 
are summarized in Fig. 4 and include, mRNA (a), intronic encoded ncRNA (b), intronic 
lariat RNA (c-d) and miRNA independently transcribed or processed from the precursor of 
the CCDC26 mRNA (e). Actually there are several regions in the CCDC26 intron where 
nucleosomal histones undergo high levels of methylation and acetylation, meaning that 
these locations may be actively transcribed (Fig.3a). Furthermore, most of these regions are 
 
Figure 4. A possible function of CCDC26. The 330-kb precursor RNA transcribed from the gene is 
processed into mature mRNA. It then forms a complex with proteins to perform its biological function, 
for example, silencing a certain genetic locus (a). Alternatively, the ncRNA independently encoded in 
the intronic region (b) or the processed intron lariat (c-d) could have biological functions. The intronic 
microRNA could be transcribed directly from the genome using its own promoter or processed from 
the precursor of the CCDC26 mRNA(e). Note that lengths of nucleic acid chains are not to scale. Length 
of the precursor RNA is approximately 330 kb; CCDC26 mRNA is 1.3 kb; the spliced lariat is more than 
100 kb; intronic microRNA is 18-23 bases. 
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highly conserved among mammals, suggesting that function is encoded. Also, expressed 
sequence tags other than known spliced CCDC26 mRNAs have been reported in the intron. 
There are three miRNAs (miR-3669, 3673 and 3686) in the intron of CCDC26 that are 
registered in the miRNA database (miRBase; http://www.mirbase.org/)(50). Although their 
functions are unknown, they may act as oncogenic or tumor suppressive ncRNAs.  
6. Hypothetical function of CCDC26 as a non-coding RNA 
Although many ncRNAs are registered in databases, only a few have clearly demonstrated 
functions and detailed mechanisms of action. CCDC26 might be a new ncRNA that is 
associated with cancer, including AML. Interestingly, expression of an miRNA, miR-21, is 
observed in many malignant cells, including AML cells (51). Also phorbol ester-induced 
differentiation of HL-60 cells into macrophage-like cells is accompanied by up-regulation of 
miR-21 (52). There are several reports suggesting that miRNAs act as oncogenic or tumor 
suppressive miRNAs in AML, as reviewed in (53, 54). Recently, Marcucci and colleagues used 
305 different probes to search for miRNA expression in favorable and adverse-risk groups of 
normal karyotype AML (monocytic leukemia). They then used these data to link expression 
profiles with the cohort analysis of the patients. They identified a certain pattern of miRNA 
expression in the adverse-risk group and linked the expression level of eight types of miRNA 
to AML prognosis (55). It is possible that an unknown miRNA in the CCDC26 locus affects 
cancer malignancy through the regulation of other genes. But all miRNAs described so far in 
the CCDC26 locus (mir-3669, mir-3673 and mir-3686) show no expression in leukemia cells and 
no conservation among mammals in contrast to other oncogenic miRNAs; for example miR21 
and let7, are actively transcribed and strongly conserved. 
Within the CCDC26 intronic region, there are some long regions (>10 kb) that are actively 
transcribed in leukemia cells (Fig. 3a). They seem to be too long for pri-miRNAs but could 
encode lncRNAs. Indeed, active transcription occurs in the CCDC26 region in cells derived 
from AML (T. Hirano unpublished observation), meaning that these transcripts might 
function as a tumor promoting or oncogenic lncRNAs. In contrast, if the original function of 
CCDC26, or of lncRNAs associated with CCDC26, was lost by chromosomal abnormality 
(for example in dmin of HL-60 cells), then they might function naturally as tumor 
suppressors. Some lncRNAs including XIST (56), KCNQ1OT1 (57), ANRIL (58) and AIRN 
(59) are known to suppress (in cis) the expression of neighboring gene. It is well known that 
genes located in extrachromosomal elements such as dmin are actively transcribed, but the 
mechanism behind this phenomenon is not well understood (60, 61). Differences between 
dmin and an intact chromosome are caused by differences in chromatin structure, which is 
indicated by differences in DNase I hypersensitivity (36). Similarly to other gene silencing 
lncRNAs, an ncRNA encoded by the CCDC26 locus might suppress the expression of other 
nearby genes. The hypothesis that neighboring genes, including the MYC oncogene, are 
activated when the normal CCDC26 locus structure is destroyed by a chromosomal 
abnormality could explain the high transcriptional activity of genes in extrachromosomal 
elements (Fig.5). Further evidence is needed to determine whether CCDC26 mRNA and/or 
its transcripts encoded in its intron are oncogenic or tumor suppressive. 
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Figure 5. Hypothetical mechanism by which an oncogene (for example MYC) is inactivated in an intact 
chromosome (a) by CCDC26 regulation. This suppression does not function on extrachromosomal 
chromatin (b). 
7. Future perspectives 
The size of the CCDC26 locus, spanning over 330,000 base pairs, makes it difficult to study. 
If the ORF of the gene is not functional then it is unclear which part(s) of the locus are 
functional. Therefore, to study this gene, it is first necessary to determine all transcripts 
produced by the CCDC26 locus and then to analyze their function. Comprehensive analysis 
of transcriptome of the relevant region using tiling microarray analysis is needed. Although 
lncRNA orthologs are frequently not found between species, homology analysis of this 
region between human and mouse could be helpful to identify functional sequences. Once 
transcripts are identified, we will be able to perform in situ hybridization to determine 
subcellular localization. Knock-down of transcripts will be useful to investigate their 
functions. Proteins interacting with the RNA transcripts will be identifiable by pull-down 
assays and mass spectrometry analysis. Finally, gene targeting should be used to investigate 
the effects of disruption of the region encoding the transcript. It will be of special interest if 
transcription of neighboring genes is activated or inactivated (in particular MYC), 
suggesting a regulatory function of the ncRNA encoded in the CCDC26 locus. If an ortholog 
of the gene is found in mice, making a knock-out mouse of the ncRNA or a transgenic 
mouse with forced expression of the ncRNA will help to demonstrate its relationship to 
disease. 
8. Conclusion 
As a conclusion, the CCDC26 locus is considered to encode an lncRNA involved in 
tumorigenesis. CCDC26 itself might be an lncRNA or its intron might contain a functional 
miRNA or lncRNA. The study of this gene will bring new knowledge to gene regulation and 
to cancer treatment strategies targeting lncRNAs. Further in vitro and in vivo study is needed 
to prove the relationship between transcripts from the locus and disease, such as leukemia 
and glioma. 
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